Cecilia Linde on Muck Rack

Cecilia Linde

Stockholm
As seen in: Arthritis & Rheumatology, Color Research & Application, Nature, Wiley Online Library, BMC Genomics, The European Heart Journal, RadcliffeCardiology.com
cardiologist, clinical scientist in the field of devices in heart failure, CRT, heart failure epidemiology , Vice President of European Society of Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cecilia

Contact Cecilia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Implementation of guideline‐recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry - Shahim - European Journal of Heart Fa

|
By Angiza Shahim, Cecilia Linde, Gianluigi Savarese, Ulf Dahlström
| Wiley Online Library Verified
Introduction Heart failure (HF) is a global public health issue leading to reduced functional status and quality of life, recurrent hospitalizations and high mortality.1 In patients with HF with reduced ejection fraction (HFrEF), several guideline-recommended HF therapies are available, including renin–angiotensin system inhibitors (RASI, i.e. angiotensin-converting enzyme inhibitors or angiotensin receptor blockers), angiotensin receptor–neprilysin inhibitor (ARNI), beta-blockers,...
Open in Who Shared Issue with article?

How to make cardiology clinical trials more inclusive - Nature Medicine

|
By Faiez Zannad, C. Michael Gibson, Cecilia Linde, Thomas F. Luscher, Thomas F. Lüscher, Richard Mindham, Maciej Kostrubiec, Bettina Johanna Kraus, André Ziegler
| Nature Verified
Abstract Cardiovascular clinical trials continue to under-represent children, older adults, females and people from ethnic minority groups relative to population disease distribution. Here we describe strategies to foster trial representativeness, with proposed actions at the levels of trial funding, design, conduct and dissemination.
Open in Who Shared Issue with article?

HF 22: Findings from the Pooled Analysis of DEFINE-HF and PRESERVED-HF

|
By Marat Fudim, Cecilia Linde, Joanna Osmanska, Tania Deis
| RadcliffeCardiology.com Verified
Video HF 22: Findings from the Pooled Analysis of DEFINE-HF and PRESERVED-HF Published: Views: 12 Likes: 0 In this short interview, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, US) shares the findings from the pooled analysis of DEFINE-HF and PRESERVED-HF.
Open in Who Shared Issue with article?
See all 30 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified